Markedly elevated levels of vascular endothelial growth factor in malignant ascites

被引:234
作者
Zebrowski, BK
Liu, WB
Ramirez, K
Akagi, Y
Mills, GB
Ellis, LM
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Houston, TX 77030 USA
关键词
ascites; vascular endothelial growth factor; angiogenesis; colon cancer; gastric cancer;
D O I
10.1007/s10434-999-0373-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that also has the ability to increase vascular permeability. Malignant ascites has significant morbidity, but the mechanism of its development is unknown. Because of the permeability-inducing properties of VEGF, we hypothesized that malignant ascites formation is associated with high levels of VEGF. The purpose of our study was to determine the role of VEGF in malignant ascites formation. Methods: Ascites from 25 patients with gastric (n = 6), colon (n = 7), or ovarian (n = 12) cancers was collected by paracentesis or surgery. VEGF protein levels were determined by enzyme-linked immunosorbent assay. The effect of ascites on endothelial cell permeability was assessed by evaluating propidium iodide uptake by human umbilical vein endothelial cells (HUVECs) exposed to ascites. Neutralizing antibodies to VEGF added to ascites were used to determine the causal effect of VEGF in permeability induction. Results: VEGF protein levels were markedly increased in malignant ascites compared with levels in nonmalignant cirrhotic ascites (controls). VEGF protein levels in ovarian, gastric, and colon cancer ascites were found to be increased 45, 23, and 12 times, respectively, compared with levels in cirrhotic ascites. Malignant ascites from patients with colon and gastric cancer caused an increase in permeability in HUVECs in all cases. Neutralizing VEGF activity in colon cancer ascites decreased in-vitro HUVEC permeability in three of four cases. Conclusions: VEGF protein levels are markedly elevated in malignant ascites. VEGF may play a role in malignant ascites formation by increasing endothelial cell permeability.
引用
收藏
页码:373 / 378
页数:6
相关论文
共 31 条
[1]   Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome [J].
Abramov, Y ;
Barak, V ;
Nisman, B ;
Schenker, JG .
FERTILITY AND STERILITY, 1997, 67 (02) :261-265
[2]  
ADAMSEN S, 1991, ACTA CHIR-EUR J SURG, V157, P325
[3]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[4]   HIGH-CONCENTRATIONS OF SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTORS IN ASCITES [J].
ANDUS, T ;
GROSS, V ;
HOLSTEGE, A ;
OTT, M ;
WEBER, M ;
DAVID, M ;
GALLATI, H ;
GEROK, W ;
SCHOLMERICH, J .
HEPATOLOGY, 1992, 16 (03) :749-755
[5]   EVIDENCE FOR THE PRODUCTION OF HIGH AMOUNTS OF INTERLEUKIN-6 IN THE PERITONEAL-CAVITY OF PATIENTS WITH ASCITES [J].
ANDUS, T ;
GROSS, V ;
HOLSTEGE, A ;
WEBER, M ;
OTT, M ;
GEROK, W ;
SCHOLMERICH, J .
JOURNAL OF HEPATOLOGY, 1992, 15 (03) :378-381
[6]   Tumor necrosis factor effects on ascites formation in an experimental tumor model [J].
Behammer, W ;
Kluge, M ;
Ruschoff, J ;
Mannel, DN .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1996, 16 (05) :403-408
[7]  
BEZWODA WR, 1989, CANCER, V64, P1029, DOI 10.1002/1097-0142(19890901)64:5<1029::AID-CNCR2820640511>3.0.CO
[8]  
2-#
[9]   EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR AND ITS RECEPTORS FLT AND KDR IN OVARIAN-CARCINOMA [J].
BOOCOCK, CA ;
CHARNOCKJONES, DS ;
SHARKEY, AM ;
MCLAREN, J ;
BARKER, PJ ;
WRIGHT, KA ;
TWENTYMAN, PR ;
SMITH, SK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (07) :506-516
[10]  
BROWN LF, 1993, AM J PATHOL, V143, P1255